{
    "nctId": "NCT05505175",
    "briefTitle": "Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC",
    "officialTitle": "TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS IN BRAZIL RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Demographical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HR+/HER2- breast cancer diagnosis with confirmed ABC/MBC\n* Received palbociclib as a first line therapy\n* No prior or current enrolment in an interventional clinical trial for ABC/MBC\n* Have a potential follow-up period of 6 months following the index date (30 days after first palbociclib prescription: palbociclib with fulvestrant and/or palbociclib with letrozole/aromatase inhibitor).\n\nExclusion Criteria:\n\n* Patients who were enrolled to receive fulvestrant but already received previous therapies",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}